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Objectives. The aim of this study was to determine whether
three-dimensional (3D) myocardial contrast echocardiography
(MCE) could provide an accurate in vivo assessment of risk and
infarct volumes.
Background. MCE has been shown to accurately define risk
area and infarct size in single tomographic slices. The ability of
this technique to measure risk and infarct volumes by using
three-dimensional echocardiography (3DE) has not been deter-
mined.
Methods. Fifteen open chest dogs underwent variable durations
of coronary artery occlusion followed by reperfusion. At each
stage, MCE was performed by using left atrial injection of AIP201, a
deposit microbubble with a mean diameter of 10 6 4 mm and a mean
concentration of 1.5z107zml21. Images were obtained over a 180° arc
with use of an automated rotational device and were stored in
computer as a 3D data set. Postmortem risk area and infarct size
were measured in six to eight left ventricular short-axis slices of
equal thickness using technetium-99m autoradiography and tissue
staining, respectively. MCE images corresponding to these planes
were reconstructed off-line.
Results. A close linear relation was noted between the volume of
myocardium not showing contrast enhancement on 3D MCE
during coronary occlusion and postmortem risk volume (y 5
1.2x 2 3.0, r 5 0.83, SEE 5 5.1, n 5 15). The volume of
myocardium not showing contrast enhancement on 3D MCE after
reperfusion also closely correlated with postmortem infarct vol-
ume (y 5 1.1x 2 3.9, r 5 0.88, SEE 5 4.8, n 5 11). No changes in
systemic hemodynamic variables were noted with injections of
AIP201.
Conclusions. When combined with AIP201, a deposit micro-
bubble, 3D MCE can be used to accurately determine both risk
and infarct volumes in vivo. This method could be used to assess
the effects of interventions that attempt to alter the infarct/risk
volume ratio.
(J Am Coll Cardiol 1997;30:1892–9)
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Myocardial contrast echocardiography (MCE) has been shown
to reliably estimate risk area during coronary occlusion in
several studies (1–8). However, these studies were performed
by using a single tomographic plane, which does not provide an
accurate assessment of the entire left ventricular (LV) risk
volume. Similarly, MCE has been demonstrated to accurately
define infarct size after reperfusion (5–11) by using the prin-
ciple that micro-vascular damage occurs within the infarction
(12–14). Again, single tomographic planes were used, which do
not necessarily reflect the size or topography of the total LV
infarct volume. Most microbubbles used in MCE behave like
red blood cells when injected arterially, and they clear the
myocardium very shortly after an arterial injection. Therefore,
to obtain an assessment of the three-dimensional (3D) topog-
raphy of risk and infarct volumes during arterial injections of
these microbubbles, several injections and images from multi-
ple views are required (3). Use of a single injection of a safe
deposit tracer would make the acquisition of the 3D data set
more convenient. We postulated that combining 3D MCE with
a stable deposit microbubble would provide accurate informa-
tion on risk volume during coronary artery occlusion and
infarct volume after reperfusion. We also assessed the effects
of this new deposit microbubble on cardiac and systemic
hemodynamics.
Methods
Animal preparation. The study protocol was approved by
the Animal Research Committee at the University of Virginia
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and conformed to the American Heart Association “Guide-
lines for Use of Animals in Research.” Fifteen adult mongrel
dogs weighing 26 to 34 kg (median 31) were anesthetized with
30 mgzkg21 of sodium pentobarbital (Abbott Laboratories).
They were intubated, and ventilated with room air by means of
a respirator pump (model 607, Harvard Apparatus) with use of
a positive end-expiratory pressure of 3 to 5 cm H2O. Addi-
tional anesthetic agents were administered during the experi-
ment as needed. A 7F catheter was placed in the femoral artery
and was connected by means of a fluid-filled transducer (model
1280C, Hewlett-Packard) to a multichannel recorder (model
4568C, Hewlett-Packard) for arterial pressure monitoring.
Two 7F catheters were also placed in the femoral veins for
intravenous administration of fluids (Plasma-Lyte A, Baxter
Healthcare Corp.) and drugs. Electrocardiographic leads were
attached in standard fashion.
A left lateral thoracotomy was performed and the heart was
suspended in a pericardial cradle. The proximal portions of the
left anterior descending (LAD) and left circumflex (LCx)
coronary arteries were dissected free from the surrounding
tissue, and umbilical tape was placed loosely around one of
them. A 7F catheter was placed in the left atrium for pressure
measurement, as well as for injections of microbubbles and
technetium-99m (Tc-99m)-labeled microalbumin aggregates.
The external jugular vein was cannulated with a 7F pulmonary
artery balloon-tipped flotation catheter (model MPA-372T,
Millar Instruments), whose tip was positioned in the proximal
pulmonary artery and connected to a cardiac output computer
(model 9520A, Edwards Laboratories). A micromanometer-
tipped catheter (model PSPC-471A, Millar Instruments) was
introduced through the left carotid artery into the left ventricle
for measurement of LV pressure and its first derivative (LV
dP/dt). Arterial blood gases were monitored throughout each
experiment (model M238, Ciba Corning, Essex, England,
United Kingdom) and kept at physiologic levels.
Hemodynamic measurements. Arterial, LV, pulmonary ar-
tery and left atrial pressures and LV dP/dt were monitored
continuously throughout the experiment. The multichannel
recorder was interfaced with a 386-based personal computer by
way of an eight-channel analog to digital converter (DAS-16,
Metrabyte). Measurements were made at baseline as well as
during coronary occlusion and reperfusion, before and repeat-
edly after contrast injection. Data were sampled at 200 Hz with
use of Labtech Notebook (Laboratory Technologies Corp.).
Cardiac output (an average of three measurements) was also
recorded immediately before and after each contrast injection.
MCE. AIP201 (Andaris Ltd., Nottingham, England,
United Kingdom) was used as the contrast agent. This agent is
formed by spraying 5% human albumin solutions, which form
air-filled bubbles with 1-mm thick denatured albumin shells.
The mean size of the bubbles is 10 6 4 mm (90% .7 mm and
0.5% $20 mm) and the mean concentration is 1.5z107zml21. It
is delivered as a white powder that is reconstituted with 5 ml of
10 mgzml21 of Tween-80. In pilot series, a dose of 10 to 15 ml
(0.3 to 0.5 mlzkg21) was found to provide optimal myocardial
opacification without system saturation or attenuation.
MCE was performed by using a phased array system (HDI
3000cv, Advanced Technology Laboratories) capable of both
fundamental imaging (ultrasound transmitted and received at
3 MHz) and harmonic imaging (ultrasound transmitted at
2.3 MHz and received at 4.6 MHz). A dynamic range of 60 dB,
a frame rate of 30 Hz and a mechanical index of 0.7 to 0.9 were
used. Images were recorded on 1.25-cm S-VHS videotape
(Panasonic AG-MD830, Matsushita Electric). A saline bath
acted as an acoustic interface between the heart and the
transducer.
MCE images for 3D reconstruction were acquired as pre-
viously described (15). The transducer was mounted in a
rubber housing and attached to a rotational device (TomTec),
which in turn was attached to a steel arm that was fixed above
the saline bath to ensure a stable position. The video output of
the ultrasound machine was connected to a 3D echocardio-
graphic (3DE) reconstruction system resident on a personal
computer (TomTec, Echo-Scan 3.0). Imaging was performed
by automatically rotating the transducer clockwise at 2° incre-
ments over a 180° arc. To achieve optimal spatial and temporal
data registration, system-based algorithms were used to ensure
that data acquisition occured at a predefined RR interval
during end-expiration. The 90 end-diastolic cross sections
sampled in this manner were digitized and stored in computer
memory.
The images were converted off-line from a polar to a
Cartesian coordinate system in a 256 3 256 3 256 pixel format
with 8-bit pixel resolution. Mathematic interpolation and stan-
dard smoothing algorithms were applied to reduce noise and
spatial artifacts. Optimal long- and short-axis views were
reconstructed from the 3D data with a slice thickness of 0.5 cm.
The perfusion defects during coronary occlusion and reperfu-
sion were planimetered at each short-axis level. The areas of
these individual slices were summed and multiplied by the sum
of the distance between adjacent planes (0.5 cm) to obtain the
total risk and infarct volumes.
Technetium autoradiography. A median of 33 min before
reperfusion, 20 to 30 mCi of 20- to 40-mm Tc-99m–labeled
microalbumin aggregates (Macrotec, Bracco Diagnostics Inc.)
were injected into the left atrium for autoradiography (16). A
clear plastic sheet was placed over the postmortem heart slices
(see later), and the epicardial and endocardial (excluding the
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papillary muscles) contours were manually drawn over the
sheet. The slices were then placed on double-emulsion X-ray
film (X-Omat AR, Eastman Kodak), which was exposed
overnight and developed with an automatic processor (M35A,
X-Omatic, Eastman Kodak). The risk area in each slice was
seen as a cold spot on the autoradiograph (Fig. 1, top panel).
The plastic sheet with the myocardial contours were placed on
the autoradiographs and the risk areas outlined on it. Risk
areas measured from each slice were summed and multiplied
by the sum of the individual slice thicknesses to obtain risk
volume.
Determination of infarct size. After Tc-99m autoradiogra-
phy, the heart was immersed in a solution of 1.3% 2,3,5-
triphenyltetrazolium chloride (Sigma Corp.) and 0.2 mmol/
liter So¨rensen’s buffer (KH2PO4 and K2HPO4 in distilled
water, pH 7.4) at 37°C for 20 to 30 min. With this technique,
noninfarcted areas are stained brick red whereas necrosed
areas remain unstained (17). The slices were arranged in the
same format as during autoradiography (Fig. 1, bottom panel),
and the same plastic sheet on which manual contours had been
drawn previously was superimposed on these slices. The infarct
areas and volume were measured and calculated with the same
method used for risk areas and volume assessment.
Experimental protocol. Either the LCx (n 5 7) or the LAD
(n 5 8) was occluded for 40 to 300 min (median 165) to cause
infarctions of varying sizes. After coronary occlusion, hemody-
namic data were acquired and the first dose of microbubbles
was injected slowly over 3 min. Hemodynamic data acquisition
was performed immediately after injection and repeated every
minute for 5 min. Subsequent acquisitions were made at
15-min intervals for 1 h. Toward the end of the occlusion
period, MCE was repeated and followed by the left atrial
injection of Tc-99m–labeled macroalbumin aggregates. Thus,
the first set of images was acquired 20 to 190 min (median 125)
after bubble injection. The occlusion was then released fol-
lowed by 20 to 200 min (median 90) of reperfusion. When the
dog was hemodynamically stable, exogenous hyperemia was
induced by an intravenous infusion of 0.4 mgzkg21zmin21 of
WRC-0470 (Discovery Therapeutics Inc.), a novel, selective,
adenosine-A2a receptor agonist (18). The second dose of
microbubbles was then injected followed by MCE data acqui-
sition 12 to 58 (median 33) min later. Hemodynamic data were
acquired in a manner similar to the occlusion stage. In pilot
studies, both fundamental and harmonic imaging were per-
formed to determine their effects on image quality. These data
were not recorded. However, in the first study dog, both forms
of imaging were recorded. Because no differences were noted
in the myocardial contrast effect between these two modalities,
harmonic imaging alone was performed in all subsequent dogs.
At the end of the experiment, the dog was killed with an
overdose of pentobarbital, and the heart was removed. It was
cut with a macrotome into six to eight equal short-axis slices
(each 0.7 to 1.0 cm thick, depending on the dog).
Statistical methods. Correlations between MCE and post-
mortem data were performed by using linear regression anal-
ysis. Hemodynamic data before and after contrast injections
were compared at each stage by using analysis of variance
(ANOVA) with repeated measures. Myocardial video intensity
(VI) data (arbitrary units, 0 to 255) were compared by using a
Student paired t test in the one dog with both harmonic and
fundamental images. A p value , 0.05 (two-sided) was con-
sidered statistically significant.
Results
Quality of myocardial opacification. Immediately after mi-
crobubble injection, contrast medium was seen in the LV
cavity, but it cleared in ,1 min. Subsequently, myocardial
opacification was excellent and remained visually unchanged
over the period of observation. Although both fundamental
and harmonic imaging were performed in only one dog, the
image quality was similar for both forms of imaging (Fig. 2). VI
averaged from the 12, 3, 6 and 9 o’clock positions measured
from images were similar in these dogs (75 vs. 78, p 5 0.65).
VI was measured in the myocardium between the first and
second injections over an interval of 60 to 240 min (median
180 min). There was no measurable change in VI (79 6 18 vs.
Figure 1. Tc-99m autoradiography (top row) and postmortem infarct
staining (bottom row) in the same heart as an example of LCx
occlusion and reperfusion. Because Tc-99m was injected during coro-
nary occlusion, all the areas with blood flow are shown in black,
whereas the risk area is depicted by the cold spots. On the tissue-
stained slices (bottom row), viable myocardium is stained brick red
whereas the infarct bed shows no staining.
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78 6 17, p 5 0.32) during this period. The second injection
only defined the smaller defect after reperfusion reflecting the
infarct size. The larger defect from the first injection reflecting
risk area was no longer seen after the second injection despite
the persistence in the myocardium of microbubbles from that
injection.
Validation of MCE perfusion defects. The risk area was
clearly seen on MCE in all dogs during coronary occlusion.
Figure 3 demonstrates the perfusion defects in several short-
axis planes that were reconstructed from a 3D data set in a dog
during LCx occlusion. Figure 4A depicts a close linear relation
between 3D MCE perfusion defects during coronary occlusion
and risk volumes derived by Tc-99m autoradiography.
After reperfusion, two dogs died before image acquisition.
In two other dogs 3D images were of insufficient quality owing
to electrical or hemodynamic instability. The data from the
remaining 11 dogs are presented in Figure 4B. A close linear
relation between 3D MCE perfusion defects during hyperemia
and postmortem-defined infarct volume was noted. Figure 5
illustrates an example of a small perfusion defect after reper-
fusion in a dog whose infarct involved the basal portion of the
LCx territory.
Hemodynamic effects. As expected, during coronary occlu-
sion and reperfusion, all dogs experienced some hemodynamic
instability. In four dogs, defibrillation was required. The injec-
tions were always performed after the dog had become hemo-
dynamically stable. No significant differences were noted in
heart rate; aortic, pulmonary artery or left atrial pressures;
Figure 2. Examples of images obtained during funda-
mental (panel A) and harmonic (panel B) imaging after
injection of AIP201.
Figure 3. Reconstructed 3D MCE data
set during LCx occlusion. Nine 0.5-cm
thick short-axis views are displayed. The
perfusion defect denoting the risk area
is depicted by arrows.
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cardiac output; or LV dP/dt for the 1-h observation period
after injection of bubbles either during coronary occlusion or
during reperfusion. Figure 6 depicts the hemodynamic vari-
ables for 1 h after microbubble injection when data from the
first and second injections were combined.
Discussion
Properties of an ideal deposit tracer. For the quantifica-
tion of myocardial blood flow, an ideal deposit tracer should
become wholly entrapped within the myocardium after left
atrial injection. The mass of the tracer entrapped in the
myocardial arterioles should be proportional to the flow to that
arteriole irrespective of its location within the myocardium.
The concentration of the tracer in myocardial regions should
thus provide an estimation of relative blood flow to these
regions. It should be possible to derive absolute blood flow to
myocardial regions by measuring the concentration of the
tracer in an arterial blood sample collected at a known flow
rate during injection of the tracer (19–21). The closest analogy
to the ideal deposit tracer is provided by radiolabeled micro-
spheres, which require postmortem tissue analysis and are thus
not suitable in the clinical setting (19).
The microbubbles used in this study are not ideal deposit
tracers because they vary widely in size. The smaller bubbles
(,5 to 6 mm) pass through the myocardium, whereas the larger
bubbles (.7 mm) are entrapped in different myocardial arte-
rioles in proportion to their size. Nonetheless, if the micro-
bubbles are homogeneously suspended, because the number
reaching a myocardial bed (including those that are entrapped)
is determined by blood flow to that region, their myocardial
distribution should provide a measure of relative flow to
different regions, provided ultrasound attenuation is also ho-
mogeneous across the heart.
Deposit tracers should not cause hemodynamic perturba-
tions within the coronary microcirculation, particularly if they
are to be used clinically. It has been demonstrated (21) that up
to 22 million 7- to 10-mm–sized radiolabeled microspheres can
be safely administered by way of the left atrium without
adverse hemodynamic effects at rest. Obviously, the number of
microspheres that can be administered without deleterious
results will be determined by their size. If the size distribution
Figure 5. Reconstructed 3D MCE data set after reperfusion in a dog
with a small infarction involving the basal portion of the LCx bed.
Eight 0.5-cm thick short-axis views are displayed. The infarct size is
depicted by arrows.
Figure 4. Relations between perfusion defect volumes obtained by 3D
MCE during coronary occlusion (A) and reperfusion (B) with post-
mortem estimates of risk and infarct volumes, respectively. See text for
details. Tc 5 technetium; TTC 5 triphenyl tetrazolium chloride.
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of the microbubbles entrapped within the coronary microcir-
culation is known, then the number of bubbles that can safely
be injected can be calculated. In this study, we did not observe
any hemodynamic alterations caused by the bubbles at rest for
the 1-h observation period after each injection. Because ours
was not a long-term study, we were not in a position to assess
the long-term hemodynamic effects or safety of these micro-
bubbles.
Deposit tracers such as Echo Gen, can also be administered
intravenously provided that at the time of injection they are
small enough to cross the lung capillaries, after which they
expand in size, becoming trapped in the myocardial microvas-
culature (6). This expansion occurs when the bubbles imbibe
gases (nitrogen and oxygen) present in blood. Inability to
control the number and size of these larger microbubbles in
vivo can result in hemodynamic perturbations due to microcir-
culatory blockage within the myocardium. At the dose at which
Echo Gen causes optimal myocardial opacification, cardiac
performance decreases even at rest (22). Importantly, at rest,
the normal myocardial microvasculature has great reserve
(23,24), and up to .80% of the microvasculature can be
effectively blocked before hemodynamic perturbations are
noted (24). In patients with ischemic heart disease, however,
the point at which this reserve is exhausted varies, and the
number of microbubbles that can be safely administered may
be much smaller.
Unlike Echo Gen, the bubbles used in our study have a
predetermined size. Because the shells of these bubbles are
very thick (1 m), gas exchange does not occur across them, and
they neither enlarge nor shrink in size. The thick shells also
preclude the destruction of the bubbles by ultrasound, even at
high acoustic pressures. Consequently, myocardial opacifica-
tion resulting from these bubbles remains unchanged for
several hours even with continuous imaging. We did not
observe any changes in myocardial opacification within the
nonoccluded bed for several hours after left atrial injections of
these bubbles.
Because AIP201 bubbles are not destroyed by ultrasound,
intermittent imaging is not necessary. Nonlinear oscillation
may also be minimal even at an optimal frequency because of
damping caused by the thick shells. Unlike other free-flowing
microbubbles, therefore, these bubbles do not require the
addition of harmonic imaging to increase the signal to noise
ratio. Although we used mostly harmonic imaging for our
study, we found no significant differences in VI between
fundamental and harmonic imaging when we used both mo-
dalities. The ability to use conventional rather than special
forms of imaging may be an added advantage of these micro-
bubbles.
Value of 3D data. Because it is a 3D structure, a single
tomographic plane cannot accurately reflect pathologic in-
volvement of the entire heart. Although multiple standard
cross sections on two-dimensional echocardiography can pro-
vide an idea of the 3D topography of risk and infarct volumes,
this approach has limitations. Parallel cross sections are diffi-
cult to obtain in adult patients because of the limited number
of acoustic windows. Because of abnormalities in the shape of
the heart afflicted with ischemic dysfunction, simple geometric
models cannot be used to calculate risk and infarct volumes.
These measurements can only be obtained from an actual 3D
data set (25–27).
In a manner similar to that used with single-photon emis-
sion computed tomography (28), we used reconstruction to
obtain the cross sections we needed. This approach is not ideal
for several reasons. 1) There are many potential sources of
artifacts. Differences in cardiac cycle lengths and cardiac
translation caused by respiration can result in inadequate data
registration. In our study, this limitation was largely overcome
by selecting cycles with a predefined length and by use of
respiratory gating. Despite these maneuvers, however, we
could not obtain adequate data in two dogs after reperfusion
because of intractable arrhythmias. 2) Any change in transducer
position during image acquisition can result in data misregistra-
tion. 3) MCE images are associated with attenuation-related
artifacts. As with single-photon emission computed tomography,
these artifacts can be magnified by the process of reconstruction.
4) The process is tedious and time-consuming. Transducer posi-
tioning alone can take up to 30 min and image analysis can take
up to several hours, depending on the quality of the images and
the level of observer experience. For these reasons, this approach
is unlikely to be used in the clinical setting in its present form.
A more ideal way to perform 3DE is by directly acquiring a
3D data set in a manner similar to that of magnetic resonance
imaging (29). One evolving strategy is the use of an array of
Figure 6. Hemodynamic data after contrast injection. Data from both
injections are included and shown as mean value (closed circles) 6
SEM (bars). AP 5 mean aortic pressure; CO 5 cardiac output; HR 5
heart rate; L 5 liters; LAP 5 mean left atrial pressure; PAP 5 mean
pulmonary artery pressure; pre 5 before injection.
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arrays that can create a 3D beam wide enough to encompass
the entire heart (30). Although the spatial resolution of this
technique is currently not as good as that of magnetic reso-
nance imaging, it has certain advantages. It can acquire the
entire data set in one cardiac cycle, thus obviating the need for
electrocardiographic or respiratory gating. It also retains the
high temporal resolution of ultrasound. Unlike magnetic res-
onance imaging, it can also be used at the bedside. The lower
equipment cost and the potentially much higher number of
patients examined within a given period makes 3DE with such
a system more economical and more practical than magnetic
resonance imaging.
Conclusions. We have described a new deposit micro-
bubble for MCE that produces excellent myocardial opacifica-
tion after left atrial injection without causing adverse hemody-
namic effects at rest at the doses used in this study. It does not
require special forms of imaging, such as harmonic imaging, to
obtain images with good myocardial opacification. Because of
its prolonged myocardial effect, it is also ideal for 3DE. With
this technique, this new agent provides accurate assessment of
risk and infarct volumes. Although these data provide only
proof of principle, we believe that this approach could be
useful in the operating room and cardiac catheterization
laboratory for assessing myocardial perfusion (31–36). In par-
ticular, it could be used to determine the effect of pharmaco-
logic and physical interventions aimed at reducing the infarct/
risk volume ratio.
We thank Norman C. Goodman, BS for technical assistance and Mr. Joseph
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